GLP-1(7-37)Acetate
GLP-1(7-37)Acetate Basic information
- Product Name:
- GLP-1(7-37)Acetate
- Synonyms:
-
- GLP-1(7-37)Acetate
- Inhibitor,inhibit,GCGR,Glucagon Receptor,GLP1(737) acetate(106612946 free base),GLP 1(7 37) acetate(106612 94 6 free base)
- CAS:
- 1450806-98-0
- MF:
- C153H232N40O49
- MW:
- 3415.77
- Mol File:
- 1450806-98-0.mol
GLP-1(7-37)Acetate Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- color
- White to off-white
- Sequence
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
- InChIKey
- YJIJUMYAXDUEKM-BVNXRIOCNA-N
GLP-1(7-37)Acetate Usage And Synthesis
Description
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1].
GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats[2].Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM[2]. Animal Model: Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variablerate for 7 hours to maintain plasma glucose concentration at 11 mM[2].
Uses
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1].
in vivo
GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats[2].
Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM[2].
| Animal Model: | Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variable rate for 7 hours to maintain plasma glucose concentration at 11 mM[2]. |
| Dosage: | 5 pmol/min/kg. |
| Administration: | IV from 1 hour through 7 hours[2]. |
| Result: | Produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle. |
| Animal Model: | Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucose concentration at 11 mM[2]. |
| Dosage: | 0.5, 5 or 50 pmol/min/kg. |
| Administration: | IV during the second hour of a 2-hour 11-mmol/L hyperglycemic clamp. |
| Result: | Produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion. |
References
[1]. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004). [2]. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7.
GLP-1(7-37)AcetateSupplier
- Tel
- 18059081430
- 2070812664@qq.com
- Tel
- info@creative-peptides.com
- Tel
- 0571-87213919
- Eric@peptidego.com
- Tel
- +1-2135480471 +1-2135480471;
- sales@sarms4muscle.com
- Tel
- 18818260767
- sales@chemegen.com